Adient plc (ADNT) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

70OpportunityDD: Jun 13, 2026Analyst: 68

paidReference price

USD 22.7 (13/06/2026)

domainMkt cap

$1.78B

pie_chartShares

78.41M

candlestick_chart52W

$14.89-$27.32

trending_downShort interest

6.5%

INFONYSEConsumer Discretionary65000 employeesFounded 2016

Verdict: Favorable Risk/Reward — Auto-parts value re-rating

#1 global automotive seating supplier post-Johnson Controls spin-off. Two consecutive Q1/Q2 FY26 beats (+52%/+18%) and raised guidance ($14.8B rev / $885M EBITDA / $130M FCF). Forward P/E 8.3x vs peer median ~8x but trading at meaningful EV/EBITDA discount given net leverage 1.8x within target. Catalyst-rich next 6 months (Q3 earnings, Citi 90-day watch, China JV ramp). Main drag: FY25 reported a -$281M net loss; turnaround is in early innings.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-06-13

Adient plc (ADNT)

Auto Parts — Seating · NYSE · Plymouth, MI

"Cyclical value with credible turnaround momentum and catalysts inside 90 days."

Forward P/E 8.3x Net leverage 1.8x in target FY25 reported loss -$281M Onshoring tailwind Beta 1.48 — cyclical

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value Estimate — SotP EV/EBITDA forward (3-segment auto parts)

Fair value base case

USD 30.1

Range: USD 22.0-USD 44.0

Reference price: USD 22.7 (13/06/2026)

Base upside/downside: +33%

Methodology: SotP EV/EBITDA forward on Americas/EMEA/Asia segments. Multiples derived from peer median (LEA 4.5x, MGA 5.0x, BWA 5.0x) with segment-level adjustments numerically justified. Implied blended multiple 4.10x vs nominal 5.0x; gap from leverage discount (-10%). Cross-check Forward P/E 8x × $3.00 EPS = $24 (−20% to SotP, leverage drag on equity). Probability-weighted FV (0.20×$44 + 0.50×$30 + 0.30×$20) = $29.80, consistent with SotP base $30.10 and analyst consensus median $27-31. ⚠️ Not investment advice.

Component	Assumption	USD/share
Americas seating EV	4.5x × $555M FY26E EBITDA (vs Lear LEA 4.5x peer)	+31.86
EMEA seating EV	3.5x × $250M FY26E EBITDA (discount: EU cyclicality + ASP pressure)	+11.16
Asia Pacific/China EV	7.0x × $260M FY26E EBITDA (premium: SCI China JV + structural growth)	+23.21
Corporate cost capitalized	−$180M overhead × 5.0x = −$900M / 78.41M sh	−11.48
Net debt @ Mar 31, 2026	($831M cash − $2,388M gross debt) / 78.41M sh	−19.86
Leverage discount (10%)	Refinancing risk vs peers @ 0.5-0.8x leverage (no specific maturity)	−4.79
FV base case	Exact sum of rows above	≈ $30.10

Bull

$42-46

Probability: 20%

FY26 EBITDA delivers $920M (above guide), Citi 90-day catalyst confirms beat, leverage drops to 1.5x; EV/EBITDA re-rates to 5.5x peer median (mix EV $5.06B − net debt $1.5B = $3.56B equity).

Base

USD 28.0-USD 32.0

Probability: 50%

Guidance executed as stated ($885M EBITDA, $130M FCF). Multiple steady at 4.8x blended, leverage maintained 1.8x. Consensus convergence to $30 by Q4 FY26.

Bear

$18-22

Probability: 30%

OEM volume slip 5-8% (US tariff drag + EV slowdown), EBITDA misses to $810M, multiple compresses to 4.0x. Refinancing 2027 revolver becomes a risk; sub-2.0x leverage breached.

Methodology: Methodology: SotP EV/EBITDA forward on Americas/EMEA/Asia segments. Multiples derived from peer median (LEA 4.5x, MGA 5.0x, BWA 5.0x) with segment-level adjustments numerically justified. Implied blended multiple 4.10x vs nominal 5.0x; gap from leverage discount (-10%). Cross-check Forward P/E 8x × $3.00 EPS = $24 (−20% to SotP, leverage drag on equity). Probability-weighted FV (0.20×$44 + 0.50×$30 + 0.30×$20) = $29.80, consistent with SotP base $30.10 and analyst consensus median $27-31. ⚠️ Not investment advice. Not investment advice.

📊 Capital Structure · Short Interest · Buyback & Dilution

🟡 Short Interest

~6.5%

~5.1M shares short vs 78.4M out. Days to cover ~3-4. Moderate — neither squeeze setup nor red flag.

🟢 Share dilution (1Y)

−2.3%

From ~80.2M to 78.4M shares. Net buyback activity — $100M repurchased FY24/H1 FY25 under $400M authorization.

🟢 Buyback

~$100M

$400M program authorized; ~$300M remaining. Priority: FCF allocated to debt paydown + buyback at 1:1 ratio.

Short Interest — context

ADNT — 6.5%

6.5%

SI at 6.5% indicates moderate skepticism — typical of mid-cycle auto-parts story stocks pre-rerating. Not a short-squeeze setup. Insider EVP sale Nov 28, 2025 noted but below $500K threshold (not material).

$Financial analysis — FY26 (FY ending Sep 30)

Revenue TTM

$14.94B

+3.9% YoY

Adj EBITDA FY26E

$885M

Raised May 6 (+$5M)

Net leverage

1.8x

In target 1.5-2.0x

Free cash flow

$130M

Modest, capex-heavy

Item	FY23	FY24	FY25	FY26 Guidance
Revenue ($B)	15.4	14.7	14.5	14.8
Adj EBITDA ($M)	900	895	870	885
Adj EBITDA margin	5.8%	6.1%	6.0%	6.0%
Reported net income ($M)	105	20	-281	~190E
FCF ($M)	240	175	110	130
Net debt ($M)	1,790	1,720	1,650	~1,500

Note: ADNT fiscal year ends September 30. FY25 reported net loss driven by impairment + restructuring (non-cash); adj EBITDA stayed at $870M. FY26 guidance raised twice (Q1 + Q2).

Quarterly dynamics — last 5 quarters
Metric	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue ($B)	3.83	3.71	3.69	3.64	3.87
Adj EBITDA ($M)	235	225	205	213	223
Adj EBITDA margin %	6.1%	6.1%	5.6%	5.9%	5.8%
Adj EPS ($)	0.49	0.41	0.52	0.35	0.52
EPS beat vs cons	-12%	-8%	-7%	+52%	+18%
End-of-period cash ($M)	820	790	760	805	831

Financial position and sustainability

Liquidity ($1.8B vs FY26 needs)

Strong

Net leverage vs target (1.8x of 2.0x cap)

At limit

FCF conversion (EBITDA→FCF)

15%

Forward P/E vs peer median

8.3x / 8.0x

account_tree

Business model — Global #1 in automotive seating

Pure-play seating supplier with global scale

Spun off from Johnson Controls in 2016, Adient is the largest dedicated automotive seating supplier worldwide (vs Lear, Magna, Toyota Boshoku). Designs and manufactures complete seating systems, frames, mechanisms, foam, head restraints, armrests, trim covers for passenger cars, trucks, vans, light commercial vehicles. Operates ~200 manufacturing/assembly facilities across 29 countries with 65,000 employees. Customer base spans nearly all major global OEMs (GM, Ford, Stellantis, VW, Toyota, BMW, Mercedes, Renault). Multi-year supply contracts with multi-year platform programs provide revenue visibility but expose the company to OEM cyclicality and ASP pressure.

Americas (US + LATAM) ~$7.4B FY26E (50% rev) 🟢 ramping Largest segment, ~$555M EBITDA at 7.5% margin. USMCA/onshoring tailwind. Recent: Romulus MI foam plant acquisition (Apr 2026), ProForce Massage launch. Customer: Big 3 + Toyota North America. EMEA ~$4.5B FY26E (30% rev) 🟡 to prove ~$250M EBITDA at 5.5% margin. ASP pressure from EU OEMs (VW, Stellantis, BMW). Margin recovery dependent on cost-out execution. Geopolitical/EV mix risk. Asia Pacific/China ~$2.9B FY26E (20% rev) 🟢 ramping ~$260M EBITDA at 9% margin — highest margin. SCI China JV (Dec 2025) accelerates BYD/local OEM penetration. Structural growth driver vs mature Americas/EMEA.

Segment EBITDA splits are estimates based on disclosed segment margins (Americas 7-8%, EMEA 5-6%, Asia 8-10%) applied to revenue mix; reconcile to total guidance $885M minus ~$180M corporate cost.

gavel

Legal, regulatory and risk analysis

Auto cycle exposure (Beta 1.48)

High

Light vehicle production volumes drive revenue 1:1. A 5-8% US/EU OEM production decline (tariff drag, consumer cooldown, EV transition pause) would shrink EBITDA by $80-130M, breaching leverage target.

OEM customer concentration

Moderate

Top 5 customers (GM, Ford, Stellantis, VW, Toyota) ~70% of revenue. Single-OEM share loss on a major platform = visible revenue gap. Mitigated by multi-platform, multi-region spread.

Net leverage at top of target

Moderate

1.8x net leverage vs 1.5-2.0x target. Gross debt $2.39B with maturities 2027-2031. No near-term wall, but refinancing in 2027 at higher rates is a watch-item if FCF dips.

FY25 reported net loss -$281M

High

Driven by impairment + restructuring charges. Reported P/E TTM 31.5x distorted; adj EBITDA remained ~$870M. Need clean GAAP profitability print in H2 FY26 to confirm turnaround thesis.

Tax asset restrictions (Nov 2025)

Moderate

Ownership-change-related Section 382 limit on NOLs flagged. Could shave FY26-27 cash tax shield by ~$15-25M but not a thesis-breaker.

Two-quarter EPS beat streak

Positive

Q1 FY26 +52% and Q2 FY26 +18% beats with raised FY guidance twice. Wells Fargo, Stifel, Barclays, UBS, Deutsche Bank, Citi all raised PTs post-Q2 — broad sell-side conviction return.

Onshoring/USMCA tailwind

Positive

Americas seating capacity already in-region (Mexico + US plants). Romulus MI foam acquisition vertical-integrates input cost. ADNT is structurally favored vs Asian-imported seating in a tariff regime.

Liquidity buffer $1.8B

Positive

$831M cash + $957M undrawn revolver. Easily covers any FY26 EBITDA shortfall, funds buyback program (~$300M remaining), and bridges 2027 refinancing. No going-concern risk.

article

SWOT analysis

Strengths

+#1 global automotive seating supplier with ~200 plants, 65K employees, 29 countries
+Forward P/E 8.3x and ~25% EV/EBITDA discount vs peer median
+2 consecutive EPS beats (+52%/+18%) with FY26 guidance raised twice
+Net leverage 1.8x within 1.5-2.0x target; liquidity $1.8B
+Onshoring/USMCA tailwind benefits Americas segment (~50% revenue)

Weaknesses

−FY25 GAAP net loss -$281M and TTM P/E 31.5x reflect ongoing restructuring
−EBITDA margin 5.8% vs peer-leader Lear ~7%, room for catch-up but execution-dependent
−Modest FCF conversion (~15% of EBITDA) due to capex intensity ($300M FY26 guide)
−EMEA segment chronic margin pressure from OEM ASP cuts

Opportunities

→SCI China JV ramp accelerates BYD/local OEM penetration in Asia
→Buyback resumption with $300M authorization remaining if FCF improves
→Re-rating to peer EV/EBITDA median ~5.0x = $44/share Bull case
→Vertical integration via Romulus foam acquisition expands captive input share

Threats

!US auto SAAR slowdown / EV transition deceleration shrinking platform volumes
!EU OEM consolidation pressure on supplier pricing (VW, Stellantis cost-out programs)
!2027 revolver refinancing at higher rates if Treasury curve stays elevated
!China JV execution risk (regulatory, JV partner alignment)

article

Summary by assessment area

🟢 Valuation — Attractive

Forward P/E 8.3x at peer median, but EV/EBITDA implies ~25% discount
SotP base FV $30.10 = +33% upside vs current $22.68
Analyst consensus $27-31, raised post-Q2 by 5+ banks

🟡 Operations — In transition

Two consecutive EPS beats validate turnaround momentum
FY25 GAAP loss reflects past restructuring; FY26 returns to net income
Asia segment is the growth engine via SCI JV; EMEA needs cost-out execution

🟡 Risk — Moderate, leverage-led

1.8x net leverage at top of target; 2027 refi risk if FCF compresses
Beta 1.48 — high cyclical exposure to US/EU auto SAAR
Catalyst path next 90 days well-defined (Q3 earnings, Citi watch)

2026-08-05 earnings

Q3 FY26 Earnings Release

short-term Impact: High Direction: Binary

Third consecutive beat would lock in FY26 guidance and likely trigger a second round of sell-side PT raises. A miss would reverse the post-Q2 momentum and reopen the leverage concern.

2026-08-15 strategic

Citi 90-day upside catalyst watch expiry

short-term Impact: Medium Direction: Bullish

Citi opened a 90-day upside catalyst watch on Adient with PT $33 (raised from $30). Watch expiry coincides with Q3 print and serves as a forced re-evaluation trigger for the sell-side.

2026-09-30 partnership

China SCI JV first-year revenue contribution

medium-term Impact: Medium Direction: Bullish

December 2025 China JV with SCI is the structural growth lever for Asia Pacific segment. First-year contribution disclosed at Q4 FY26 sets the runway for the segment's premium 7.0x multiple in SotP.

2026-11-04 earnings

FY26 Full-Year Results & FY27 Guidance

medium-term Impact: High Direction: Binary

First clean GAAP profitability print after FY25's -$281M loss. FY27 EBITDA guidance the most important number — consensus needs $920M+ to validate Bull case multiple expansion.

2026-11-15 capital_markets

Buyback program acceleration decision

medium-term Impact: Medium Direction: Bullish

~$300M remaining on $400M buyback authorization. With FY26 FCF $130M and net debt declining, management decision to accelerate vs preserve dry-powder for refi materially affects shareholder return.

2026-12-15 regulatory

USMCA renegotiation outcome

medium-term Impact: High Direction: Binary

Bullish if rules-of-origin tighten and content thresholds favor in-region production (ADNT's Mexico/US footprint). Bearish if tariff escalation broadly disrupts North American OEM volumes.

2027-03-31 capital_markets

2027 revolver refinancing window opens

long-term Impact: High Direction: Neutral

Adient's revolver matures 2027. Refinancing terms (spread vs prior, capacity, covenant suite) directly impact leverage discount currently baked into the SotP fair value.

{ "verdict_label": {"it": "Giudizio: Risk/Reward Favorevole", "en": "Verdict: Favorable Risk/Reward"}, "verdict_text": {"it": "Adient (ADNT) — #1 seating globale: forward P/E 8.3x, sconto ~25% EV/EBITDA vs peer. Due beat consecutivi +52%/+18%, guidance FY26 alzata due volte. FV base $30.10 (+33%) con catalizzatori a 90 giorni.", "en": "Adient (ADNT) — global #1 seating supplier: forward P/E 8.3x, ~25% EV/EBITDA discount to peers. Two consecutive EPS beats (+52%/+18%) with FY26 guidance raised twice. Base FV $30.10 (+33%) with catalysts inside 90 days."}, "bull_points": [ {"it": "Forward P/E 8.3x con sconto EV/EBITDA ~25% vs mediana peer auto-parts.", "en": "Forward P/E 8.3x with ~25% EV/EBITDA discount vs auto-parts peer median."}, {"it": "Beat consecutivi Q1/Q2 FY26 e guidance FY26 alzata due volte ($14.8B / $885M EBITDA).", "en": "Q1/Q2 FY26 EPS beats and FY26 guidance raised twice ($14.8B rev / $885M EBITDA)."}, {"it": "Catalizzatori a 90 giorni: Q3 earnings, Citi catalyst watch, ramp JV Cina SCI.", "en": "90-day catalyst lineup: Q3 earnings, Citi catalyst watch, China SCI JV ramp."} ], "bear_points": [ {"it": "FY25 net loss GAAP -$281M ancora visibile sul P/E TTM 31.5x.", "en": "FY25 GAAP net loss -$281M still visible in 31.5x TTM P/E."}, {"it": "Leva netta 1.8x al limite superiore del target 1.5-2.0x; rifinanziamento 2027.", "en": "Net leverage 1.8x at top of 1.5-2.0x target; 2027 revolver refi ahead."}, {"it": "Beta 1.48 e concentrazione top-5 OEM ~70% revenue: vulnerabile a SAAR slowdown.", "en": "Beta 1.48 and top-5 OEM concentration ~70% revenue: vulnerable to SAAR slowdown."} ], "risks": [ {"it": "Ciclo auto US/EU: -5/-8% volumi OEM tagliano EBITDA di $80-130M.", "en": "US/EU auto cycle: -5/-8% OEM volumes cut EBITDA by $80-130M."}, {"it": "EMEA cronicamente sotto pressione margine da ASP cuts OEM.", "en": "EMEA chronically pressured by OEM ASP cuts."}, {"it": "Rifinanziamento revolver 2027 a tassi più elevati se Treasury curve resta alta.", "en": "2027 revolver refi at higher rates if Treasury curve stays elevated."} ] }

Sources & Disclaimer

Sources: Stock Analysis (stockanalysis.com), TradingKey, CNN Markets, MacroTrends, ChartMill, StockTitan, Seeking Alpha, TheFly via TipRanks, Adient Q2 FY26 press release (May 6, 2026), PRNewswire (Romulus MI acquisition Apr 27, 2026; SCI JV Dec 8, 2025), INDmoney. Market data — last verified close 2026-06-12: ADNT $22.68 (+1.11%), market cap ~$1.78B, 52W: $14.89-$27.32, 78.41M shares outstanding. Short interest ~6.5%. Net debt $1.6B, leverage 1.8x TTM EBITDA. FY26 guidance: $14.8B revenue, $885M adj EBITDA, $130M FCF (raised May 6, 2026). Analyst consensus median $27-31 (13-23 sell-side, raised post-Q2). ⚠️ This document is for informational purposes only and does not constitute financial or investment advice.